What do we know about the new #SARSCoV2 variants? How worried should we be? What does it mean?
I promised to summarize the main points from my reporting over the last few days.
So here is my latest story and a thread (and then it’s Christmas) sciencemag.org/news/2020/12/u…
First: I’ve said “We don’t know yet” a lot over the last few days and we still don’t know most of what we want to know about these variants. Getting good answers takes times. Science takes time. But we are learning a lot fast and we know a lot more today than three days ago.
The UK variant:
I explained how B.1.1.7 caught scientists’ attention in my first story on this and why they were worried (sciencemag.org/news/2020/12/m…).
That worry has only increased. There is now more data available and it points to this variant really being more transmissible.
Initially skeptical scientists like @c_drosten have become more convinced. As @mugecevik told me: “We can’t really rule out the possibility that seasonality and human behavior explain some of the increase. But it certainly seems like there is something to do with this variant.”
@c_drosten@mugecevik This is about transmissibility. For now there is little to suggest it causes more severe disease or evades immunity. Scientists I spoke to can see a variant like this shaving a few points off efficacy of a vaccine but not dramatically reducing it. Experiments will tell us soon.
@c_drosten@mugecevik As @profshanecrotty pointed out the body makes a broad response to #SARSCoV2 and even just the spike protein. “It would be a real challenge for a virus to escape from that.” Measles and polio vaccines still work and are "historical examples suggesting not to freak out.”
@c_drosten@mugecevik@profshanecrotty Increased transmissibility is still really bad news. It’s not clear how much more transmissible the variant really is. But the numbers that modellers have come up with are worrying. Our job to keep the numbers down until people are vaccinated has likely become a fair bit harder.
@c_drosten@mugecevik@profshanecrotty How does the increase in transmission come about? We don’t know. There are several hypotheses: the variant might infect children better than previous variants. It might transmit faster. @BillHanage has a great thread on a preprint looking at this.
@c_drosten@mugecevik@profshanecrotty@BillHanage The South African variant: We know less about 501Y.V2. This variant too seems to be spreading faster and there is anecdotal (meaning very weak) evidence of more severe disease in younger, healthy people. @JeremyFarrar told me he was at least as concerned about this variant. Why?
@c_drosten@mugecevik@profshanecrotty@BillHanage@JeremyFarrar 1. It has 3 mutations in the RBD, an important part of the spike protein. All seem a bit worrying by themselves and we don’t know what the combination means. @JeremyFarrar: "These South African mutations I think are more worrying than the constellation of the British variant"
@c_drosten@mugecevik@profshanecrotty@BillHanage@JeremyFarrar 2. Africa has largely escaped the brunt of this pandemic. Many scientists think younger age and warmer climate together with other factors make #SARSCoV2 spread less efficiently there. Worry is that an increase in transmissibility could get over these factors.
@c_drosten@mugecevik@profshanecrotty@BillHanage@JeremyFarrar Discovery: The UK has sequenced more #SARSCov2 viruses and done so faster than any other country. The story shows how important and helpful genomic surveillance can be and that we are affording ourselves an awful lot of blindspots in this pandemic.
@c_drosten@mugecevik@profshanecrotty@BillHanage@JeremyFarrar There are already indications that the last few days have prompted many countries to sequence more, release more data. So if there is a flurry of new variants/mutations announced in the next days and weeks that is partly because we are now looking more closely/sharing more.
@c_drosten@mugecevik@profshanecrotty@BillHanage@JeremyFarrar Origin: Most likely hypothesis for now is that these variants arose in patients whose immune system was weakened and who were infected over a long period of time. “It’s simply too many mutations to have accumulated under normal evolutionary circumstances”, @stgoldst told me.
@c_drosten@mugecevik@profshanecrotty@BillHanage@JeremyFarrar@stgoldst@jbloom_lab There probably needs to be more debate about how best to care for such chronically infected, immunocompromised patients, what treatments make sense and how to make sure they don’t transmit onwards late in the infection. I also hope we get more research on virus evolution in them.
Some good news (and incredibly fast work) on one of the mutations scientists are worried about: N501Y.
In these lab experiments serum from recovered #covid19 patients was just as good at neutralizing virus with the mutation as without it.
This does not say anything about whether the mutation could make the virus more transmissible but it suggest the mutation alone at least does not mean the virus can widely infect people again.
Of course, both UK and SA variant have several additional mutations...
I will let other people figure out how to cite a tweet in a scientific publication ;)
It’s becoming clearer that one main hypothesis that scientists are looking at with B.1.1.7 is whether its advantage could be that it is better at infecting children. There are a TON of caveats, but this is one possibility that is being explored.
The idea is very simple: #SARSCoV2 appears to be a bit worse at infecting children than adults. If the mutations in B.1.1.7 allow this variant to bind more tightly to the ACE2 receptor on human cells that could essentially make it as good at infecting children as adults.
Like I said a TON of caveats. Maybe most importantly: the UK had a lockdown while schools were kept open, so you would expect the epidemic to shift more to children anyway and that of course can make it look like there is something going on with this variant in children.
There’s a lot of concern and confusion right now about the new #sarscov2 variant identified in UK. I’ve spent today and yesterday talking to a dozen people working on this. My story is here: sciencemag.org/news/2020/12/m…
Thread to come (may be long and slow)
There are a ton of things to explain, dozens of questions to discuss and I won’t be able to cover more than a tiny part here now. So three general things up front: 1. Expect more threads and stories on this from me
“We urge governments throughout Europe to agree on clearly formulated common goals, coordinate their efforts, develop regionally adapted strategies to reach the goals, and thereby work resolutely towards low case numbers”, @CiesekSandra, @ViolaPriesemann and others in @TheLancet
The lack of a European strategy is something scientists and public health experts have pointed out again and again and it’s good to see it clearly formulated by a group of prominent researchers thelancet.com/journals/lance…
The authors also give a good, succinct summary of arguments for going for low #covid19 case numbers: 1. saving lives 2. saving the economy 3. control is more effective 4. makes TTI feasible 5. natural acquired herd immunity is not an option 6. no need for rapid policy changes
Meine Kollegen vom @pandemiapodcast und ich haben viele Fragen bekommen in den vergangenen Wochen zu den neuen Impstoffen, zu ihrer schnellen Entwicklung, ihrer Sicherheit, zu Impfbereitschaft und Impfpflicht. Wir wollten das natürlich aufnehmen.
@pandemiapodcast Die neue Folge ist darum ein etwas wilder Ritt querfeldein und wir binden zusammen, worüber wir in den ersten Folgen der zweiten Staffel gesprochen haben: Impfstoffe, Pocken, Masern und eben #SARSCoV2. Die Folge gibt es hier: viertausendhertz.de/pan16/
Als Nächstes dann Gelbfieber!
Global vaccine news: COVAX says deals are in place to access nearly 2 billion doses of #covid19 vaccine. "For the vast majority of these deals, COVAX has guaranteed access to a portion of the first wave of production, followed by volume scales as further supply becomes available”
The new deals include:
- an advance purchase agreement with AstraZeneca for 170 million doses of the AstraZeneca/Oxford candidate
- a memorandum of understanding (MoU) with Johnson & Johnson for 500 million doses of the Janssen candidate (investigated as single dose vaccine)
That’s on top of:
- agreement with Serum Institute of India for 200 million doses (plus option for 900 million more doses) of either AZ or Novavax vaccine
- statement of intent for 200 million doses of Sanofi/GSK vaccine candidate